TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22525081

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine formulation (31.5 mg) administered intranasally
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nasal inhalation (gentle or vigorous sniff)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nasal spray pump delivery device
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nasal cavity clearance
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Gentle inhalation
Number of subjects: 13
Study: 19895623

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 220
Study: 17931895

Group type: EXPERIMENTAL
Intervention: EPOCA prosthesis (fixation with wire cables)
Number of subjects: 35

Group type: COMPARATOR
Intervention: HAS prosthesis (fixation with transosseous braided sutures)
Number of subjects: 35
Study: 16000624

Group type: EXPERIMENTAL
Intervention: Propranolol (beta‐adrenoceptor antagonist)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Reboxetine (selective norepinephrine reuptake inhibitor)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 11916759

Group type: EXPERIMENTAL
Intervention: Vitamin A (1500 retinol equivalents or 5000 IU) and Zinc (15 mg) supplementation daily for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10401802

Group type: EXPERIMENTAL
Intervention: CATCH intervention
Number of subjects: 3714

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3714
Study: 7564449

Group type: EXPERIMENTAL
Intervention: Warm antegrade delivery of cardioplegic solution (N = 25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Warm retrograde delivery of cardioplegic solution (N = 25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination of warm antegrade and retrograde delivery of cardioplegic solution (N = 25)
Number of subjects: 75
Study: 1675049

Group type: EXPERIMENTAL
Intervention: 0.3% flurbiprofen
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1% apraclonidine hydrochloride
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 18
Study: 7023308

Group type: EXPERIMENTAL
Intervention: Digoxin treatment for 8 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 15
Study: 31874733

Group type: EXPERIMENTAL
Intervention: Exercise-based injury prevention program (IPP) performed for eight weeks at training
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (continued usual cricket activity)
Number of subjects: 65
Study: 30613990

Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine (4.3 log plaque-forming unit)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine (4.7 log plaque-forming unit)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine (4.9 log plaque-forming unit)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28400181

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 24
Study: 25407688

Group type: EXPERIMENTAL
Intervention: Zen meditation (MG) - meditated twice a day for 20 minutes for 3 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (CG) - remained on a waiting list
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Zen meditation (MG)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 59
Study: 24197403

Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up
Number of subjects: 359

Group type: COMPARATOR
Intervention: Control group (in-clinic follow-up only)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Comparison of pacemaker replacements
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Overall patient outcomes
Number of subjects: 359
Study: 21353462

Group type: EXPERIMENTAL
Intervention: Williams syndrome (WS) subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mental age‐matched control children
Number of subjects: 0
Study: 19692317

Group type: EXPERIMENTAL
Intervention: Intravesical BCG treatment (81 mg for 6 weeks)
Number of subjects: 41
Study: 17206567

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy after partial duodenopancreatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard lymphadenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 0
Study: 14687272

Group type: EXPERIMENTAL
Intervention: Positive frame video
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Neutral frame video
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Negative frame video
Number of subjects: 179
Study: 10755174

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 9332992

Group type: EXPERIMENTAL
Intervention: Prophylactic saline amnioinfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cases (no amnioinfusion)
Number of subjects: 0
Study: 8223740

Group type: EXPERIMENTAL
Intervention: Prazosin (0.25 mg and 0.50 mg)
Number of subjects: 8
Study: 2880458

Group type: EXPERIMENTAL
Intervention: Oxypertine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31054038

Group type: EXPERIMENTAL
Intervention: Bioimpedance Spectroscopy (BIS)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Tape Measurement (TM)
Number of subjects: 508
Study: 29713909

Group type: EXPERIMENTAL
Intervention: Rifaximin (600 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27435761

Group type: EXPERIMENTAL
Intervention: Capecitabine 1500 mg/daily continuously with rabeprazole 1.5 mg/kg twice a day, 3 days a week
Number of subjects: 66

Group type: COMPARATOR
Intervention: Capecitabine 1500 mg/daily continuously without rabeprazole
Number of subjects: 66
Study: 24666633

Group type: EXPERIMENTAL
Intervention: Mothers In Motion (MIM) intervention group
Number of subjects: 525

Group type: COMPARATOR
Intervention: Comparison group (printed educational materials)
Number of subjects: 525
Study: 23291025

Group type: EXPERIMENTAL
Intervention: Early continuous high-volume-hemofiltration
Number of subjects: 60
Study: 20118792

Group type: EXPERIMENTAL
Intervention: Landiolol (continuous administration during anesthesia)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (no landiolol except bolus for uncontrolled tachycardia)
Number of subjects: 56
Study: 18590431

Group type: EXPERIMENTAL
Intervention: Skull block with 0.5% ropivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no skull block)
Number of subjects: 30
Study: 15676092

Group type: EXPERIMENTAL
Intervention: Mild hypothermia therapy (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normothermia therapy (n=20)
Number of subjects: 40
Study: 11846857

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg twice/day for 6 days along with 0.4 mg digoxin on study day 5
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12132546

Group type: EXPERIMENTAL
Intervention: Higher death distress
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Death distress
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Psychosocial-spiritual dimensions
Number of subjects: 70
Study: 9893777

Group type: EXPERIMENTAL
Intervention: Early extubation (Group A) with mechanical ventilatory support for 4‐7 h
Number of subjects: 144

Group type: COMPARATOR
Intervention: Routine extubation (Group B) with mechanical ventilatory support for 8‐14 h
Number of subjects: 144
Study: 8279616

Group type: EXPERIMENTAL
Intervention: Individual skin screening by a dermatologist and education session; n = 65
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group; n = 77
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both groups improved in knowledge score; n = 142
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both groups; n = 142
Number of subjects: 142
Study: 2500401

Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 36

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 36
Study: 31104039

Group type: EXPERIMENTAL
Intervention: Tailored and integrated violence prevention program in psychiatric wards and prisons
Number of subjects: 0
Study: 28340244

Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg/d for 7 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (for 7 days)
Number of subjects: 17
Study: 25469804

Group type: EXPERIMENTAL
Intervention: Candesartan (target dose 16 mg/d)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 23884659

Group type: EXPERIMENTAL
Intervention: CJ leflunomide 10 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CJ leflunomide 20 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Arava® (reference drug)
Number of subjects: 56
Study: 21149288

Group type: EXPERIMENTAL
Intervention: Multimedia website
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing brochure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-brochure and non-website users
Number of subjects: 0
Study: 18243516

Group type: EXPERIMENTAL
Intervention: Combined high-dosed antimuscarinics
Number of subjects: 27
Study: 16870004

Group type: EXPERIMENTAL
Intervention: Hot skimmed milk formulation (15 mg zeaxanthin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Warm skimmed milk formulation (15 mg zeaxanthin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hot water formulation (15 mg zeaxanthin)
Number of subjects: 12
Study: 14768141

Group type: EXPERIMENTAL
Intervention: Laparoscopic exploration
Number of subjects: 34

Group type: COMPARATOR
Intervention: Open surgical exploration
Number of subjects: 34
Study: 10851837

Group type: EXPERIMENTAL
Intervention: One dose of vitamin A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 9166880

Group type: EXPERIMENTAL
Intervention: Swallowing therapy with videoendoscopic biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional swallowing therapy
Number of subjects: 0
Study: 8246577

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.3 microgram/kg
Number of subjects: 112

Group type: COMPARATOR
Intervention: Saline solution placebo
Number of subjects: 112
Study: 30476999

Group type: EXPERIMENTAL
Intervention: Cerebellar intermittent θ‐burst stimulation (CRB‐iTBS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 36
Study: 29195573

Group type: EXPERIMENTAL
Intervention: TAVR with CoreValve bioprosthesis
Number of subjects: 797

Group type: COMPARATOR
Intervention: SAVR with surgical bioprosthetic valve
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 797

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Both TAVR and SAVR
Number of subjects: 797
Study: 25978852

Group type: EXPERIMENTAL
Intervention: 400 μg Folic Acid
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: 800 μg Folic Acid
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: 3 g Creatine
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: 3 g Creatine + 400 μg Folic Acid
Number of subjects: 622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622
Study: 22984216

Group type: EXPERIMENTAL
Intervention: Culturally tailored HIV prevention intervention (six group-based sessions and one individual session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (single-session HIV prevention review)
Number of subjects: 0
Study: 20433248

Group type: EXPERIMENTAL
Intervention: Liposomal 3% prilocaine
Number of subjects: 32

Group type: COMPARATOR
Intervention: 3% plain prilocaine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 3% prilocaine with 0.03IU/mL felypressin
Number of subjects: 32
Study: 19939302

Group type: EXPERIMENTAL
Intervention: Life completion discussion intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Attention control (relaxation meditation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 18
Study: 16750464

Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension 0.03%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension 0.1%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diclofenac sodium ophthalmic solution 0.1%
Number of subjects: 60
Study: 15142073

Group type: EXPERIMENTAL
Intervention: Vaseline applied twice a day bilaterally for 4 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (simple observation with an 8-week appointment)
Number of subjects: 105
Study: 11312048

Group type: EXPERIMENTAL
Intervention: 1 mg morphine into inflamed submucous tissue
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1 mg morphine into non-inflamed tissue
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1 mg morphine perineurally
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (articaine plus saline) for inflamed tissue
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (articaine plus saline) for non-inflamed tissue
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (articaine plus saline) for perineural tissue
Number of subjects: 96
Study: 9202804

Group type: EXPERIMENTAL
Intervention: Aerosolized furosemide (2 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 8
Study: 8187026

Group type: EXPERIMENTAL
Intervention: Inhaled phosphoramidon (10(-5) M)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Inhaled NKA
Number of subjects: 6
Study: 3307881

Group type: EXPERIMENTAL
Intervention: Budesonide (100 micrograms b.i.d.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (100 micrograms b.i.d.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29454601

Group type: EXPERIMENTAL
Intervention: Cross-linked polyethylene
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ultra-high molecular weight polyethylene (UHMWPE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both types of inserts
Number of subjects: 25
Study: 27666137

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer cement without heat application (HVGIC)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: LED thermocured high-viscosity glass-ionomer cement (HVGIC)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 801
Study: 25343850

Group type: EXPERIMENTAL
Intervention: Whey protein/fibre preload (17 g whey protein, 3 g lactose, 5 g guar, 1 g flavour material in 150 ml cold water)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (150 ml cold water with no additives)
Number of subjects: 24
Study: 23755872

Group type: EXPERIMENTAL
Intervention: 6 hours of daily patching
Number of subjects: 169

Group type: COMPARATOR
Intervention: 2 hours of daily patching
Number of subjects: 169
Study: 20692161

Group type: EXPERIMENTAL
Intervention: Congruent Stroop condition with perturbed proprioceptive inputs
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Non-congruent Stroop condition with perturbed proprioceptive inputs
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Congruent Stroop condition without perturbed proprioceptive inputs
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Non-congruent Stroop condition without perturbed proprioceptive inputs
Number of subjects: 36
Study: 18057088

Group type: EXPERIMENTAL
Intervention: Preoperative inspiratory muscle training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 20
Study: 16849865

Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation and Management Unit (GEMU)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Medical Wards (MW)
Number of subjects: 254
Study: 14682552

Group type: EXPERIMENTAL
Intervention: Slider shoe
Number of subjects: 4

Group type: COMPARATOR
Intervention: Baseline phase (A1)
Number of subjects: 4
Study: 11057391

Group type: EXPERIMENTAL
Intervention: Synthetic mattress covers (polyester microfaser with polyurethane surface layer)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cotton mattress covers
Number of subjects: 84
Study: 9029898

Group type: COMPARATOR
Intervention: Mucinous adenocarcinoma (Group 1)
Number of subjects: 58
Study: 1503519

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (hGH; 0.3 U/kg/24 hours)
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 6510453

Group type: EXPERIMENTAL
Intervention: Penbutolol (40 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sustained-release metoprolol (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study: 30616674

Group type: EXPERIMENTAL
Intervention: Self-selected music
Number of subjects: 170

Group type: COMPARATOR
Intervention: Predetermined music from MUSIC CARE®
Number of subjects: 170
Study: 27770155

Group type: EXPERIMENTAL
Intervention: BMD fast track program with full fracture risk assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMD fast track program
Number of subjects: 0
Study: 25781198

Group type: EXPERIMENTAL
Intervention: Arginine-based supplement (3.0 g of arginine, 300 mg of grape seed extract, and 300 mg of polyethylene glycol)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Arginine-based supplement
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 25118795

Group type: EXPERIMENTAL
Intervention: PrEP (Tenofovir)
Number of subjects: 1785
Study: 22351374

Group type: EXPERIMENTAL
Intervention: Referral for CRC screening
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Completion of CRC screening
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Readiness to change
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Comorbid conditions
Number of subjects: 159
Study: 19542795

Group type: EXPERIMENTAL
Intervention: IVPCA morphine plus ketorolac (M+K group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: IVPCA morphine (M group)
Number of subjects: 102
Study: 17337467

Group type: EXPERIMENTAL
Intervention: HP10 antigen detection ELISA applied to serum
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HP10 antigen detection ELISA applied to cerebrospinal fluid (CSF)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: HP10 antigen detection ELISA
Number of subjects: 116
Study: 12510800

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg
Number of subjects: 437

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study: 11020183

Group type: EXPERIMENTAL
Intervention: 3-dimensional airway CT
Number of subjects: 50
Study: 9049514

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg b.d.
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 2006

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2006
Study: 8350705

Group type: EXPERIMENTAL
Intervention: Walking group (exercised 30-40 min, 5 days/week for 12 weeks at 60% heart rate reserve)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Calisthenic group (engaged in mild range-of-motion and flexibility movements for 12 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Highly conditioned group (cross-sectional comparison)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Walking group
Number of subjects: 32
Study: 3524550

Group type: EXPERIMENTAL
Intervention: Laminaria tents
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intracervical PGF2 alpha gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 60
Study: 29684661

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU monthly)
Number of subjects: 2494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2494
Study: 26671622

Group type: EXPERIMENTAL
Intervention: Bandage contact lenses (BCLs)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Topical ganciclovir 0.15% gel
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Topical 0.4% povidone-iodine solution
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Topical steroids
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Preservative-free artificial tears and topical antibiotics
Number of subjects: 15
Study: 24648018

Group type: EXPERIMENTAL
Intervention: Telephone session attendance
Number of subjects: 641
Study: 22591726

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Induction chemotherapy plus radiotherapy (IC+RT)
Number of subjects: 400
Study: 20528796

Group type: EXPERIMENTAL
Intervention: 500mL of 100% mandarin juice daily
Number of subjects: 40
Study: 18760064

Group type: EXPERIMENTAL
Intervention: Mueller‐Hinton agar with cefoxitin 30 microg disc
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iso‐sensitest agar with cefoxitin 30 microg disc
Number of subjects: 100
Study: 15924512

Group type: EXPERIMENTAL
Intervention: Water-based exercise and self-management program (10-week duration, conducted twice a week for one hour)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Water-based exercise and self-management program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 12873574

Group type: EXPERIMENTAL
Intervention: Patients with food allergy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 29
Study: 11045306

Group type: EXPERIMENTAL
Intervention: Mupirocin application during the mupirocin period (group I)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Mupirocin application during the mupirocin period (group II)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Historical control data (group I before mupirocin application)
Number of subjects: 42
Study: 8788291

Group type: EXPERIMENTAL
Intervention: High-lipase enteric-coated microsphere preparation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-lipase enteric-coated microsphere preparation
Number of subjects: 20